Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
168.39(c) 169.69(c) 171.3(c) 172.11(c) 171.28(c) Last
2 144 250 2 249 305 2 615 458 2 902 510 2 319 660 Volume
-0.89% +0.77% +0.95% +0.47% -0.48% Change
More quotes
Financials (USD)
Sales 2019 22 583 M
EBIT 2019 10 804 M
Net income 2019 7 636 M
Debt 2019 699 M
Yield 2019 3,32%
Sales 2020 22 757 M
EBIT 2020 11 090 M
Net income 2020 8 071 M
Finance 2020 3 397 M
Yield 2020 3,52%
P/E ratio 2019 14,02
P/E ratio 2020 13,06
EV / Sales2019 4,68x
EV / Sales2020 4,46x
Capitalization 105 B
More Financials
Company
Amgen is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.9%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 77.3% of net sales; - other (5.1%):... 
Sector
Pharmaceuticals
Calendar
06/01 | 02:15pmPresentation
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
05/22AMGEN : to Buy Danish Biotech Nuevolution for $167 Million
DJ
05/22AMGEN : announces a recommended public cash offer to the shareholders of Nuevolu..
PR
05/21AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/21AMGEN : Announces Voting Results Of Annual Meeting Of Stockholders
PR
05/20AMGEN : Investor Insights Newsletter Q1 2019
PU
05/16AMGEN : To Present At The RBC Healthcare Conference And The UBS Global Healthcar..
PR
05/16MIRATI THERAPEUTICS : Shares Jump 17% on Rival Amgen's Progress on Potential Can..
DJ
05/16AMGEN : Ex-dividend day for
FA
05/15AMGEN : Showcases Oncology Pipeline At ASCO 2019
PU
05/15Drugmakers Settle U.S. Patent Dispute Over Clone of Humira -- WSJ
DJ
More news
Analyst Recommendations on AMGEN
More recommendations
Stock Trading Strategies
AMGEN - 2018
Comeback of a rising trend ?
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
05:14pNOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
04:36pNOVARTIS : Correction to Novartis Article
DJ
03:33pNOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
02:26pNOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
02:07pSAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 205 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN-12.00%104 976
JOHNSON & JOHNSON7.52%371 150
PFIZER-3.80%233 072
ROCHE HOLDING LTD.10.72%230 177
NOVARTIS14.01%212 054
MERCK AND COMPANY6.03%208 598